Enliven Therapeutics – Talk Bio

Actionable Insights Powered by AI

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

3 weeks ago talkbio0Tagged asciminib, BCR-ABL1, Contraceptives, Oral, Deep molecular response, ELVN-001, ENABLE trial, Enliven Therapeutics, Inhibitor, Measles-Mumps-Rubella Vaccine, Molecular Response, Myeloid Leukemia, Chronic, Novartis, Phase 1b, Protein-tyrosine kinase inhibitor, T315I, TERN-701, Terns, TKI, WDR20 gene

Enliven Therapeutics; ELVN-001; Phase 1b; chronic myeloid leukemia; CML; BCR-ABL1 inhibitor; major molecular response; MMR; deep molecular response; DMR; asciminib; Novartis; Terns Pharmaceuticals; TERN-701; T315I; ENABLE trial; CML pill; tyrosine kinase inhibitor; TKI; best-in-class

Enliven Therapeutics Announces New CEO

2 months ago talkbio0Tagged CEO, ELVN, Enliven Therapeutics, Leadership, Myeloid Leukemia, Chronic, Phase 3 trial, Richard Fair, Rick Fair, Transition Mutation

Enliven Therapeutics; ELVN; new CEO; Rick Fair; Richard Fair; Sam Kintz; leadership transition; Phase 3 trial; ELVN-001; chronic myeloid leukemia; CML; biotech; Nasdaq ELVN